341 results about "Somatotropic hormone" patented technology

The invention provides an application of bifidobacterium animalis subsp. Lactis CP-9 in preparation of a product for promoting bone growth and development or improving bone health. Long-term research and a large number of experiments show that the bifidobacterium animalis subsp. Lactis CP-9 can improve the bone volume fraction, the bone trabecula thickness, the bone density and the bone volume of an organism, and can also effectively improve the growth hormone level and the insulin-like growth factor 1 level, so that bone growth and development are promoted. Meanwhile, the bifidobacterium animalis subsp. Lactis CP-9 can effectively improve the N-terminal propeptide level, osteocalcin level, bone morphogenetic protein level and osteoprotectin level of I-type procollagen in a body, and remarkably reduce the amino-terminal peptide level of the I-type collagen and the ligand level of nuclear factor kappa B receptor activating factor, so that osteoblast differentiation is promoted, osteoclast differentiation is inhibited, and osteoclast differentiation is inhibited. Furthermore, bone formation is promoted, bone resorption is inhibited, bone metabolism is improved, and finally the effect of improving bone health is achieved.

The invention relates to the technical field of microorganisms and bio-organic fertilizers, and particularly discloses a bio-organic fertilizer for preventing and treating rhizome diseases of horseradish and application of the bio-organic fertilizer, the bio-organic fertilizer comprises the following components: component A: a bacillus velezensis microbial inoculum with the preservation number of CCTCC NO: M 2022923 and a trichoderma yunnanense microbial inoculum with the preservation number of CCTCC NO: M 2025645; the component B is prepared from soybean meal, vinegar residues, charcoal, wollastonite powder and allicin. The biological organic fertilizer disclosed by the invention can be used for increasing the content of growth hormones such as salicylic acid (SA), jasmonic acid (JA) and ethylene (ET) and phytoalexin as well as the activity of chitinase and beta-1, 3-glucanase of a wasabi root system, and has a relatively good prevention and treatment effect on a black heart disease caused by infection of phoma wabi Yokog and a soft rot disease caused by infection of pectobacterium carotovorum subsp. Carotovorum (Pcc). The biological organic fertilizer disclosed by the invention has a relatively good prevention and treatment effect on the soft rot disease caused by infection of the phoma wabi Yokog and a relatively good prevention and treatment effect on the soft rot disease caused by infection of the phoma wabi subsp. Carotovorum (Pcc).

Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.

Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.

The invention discloses a freeze-drying method of long culture growth hormone, which comprises the following steps: adding a middle plug into a double-cavity clamping bottle, filling the double-cavity clamping bottle with the long culture growth hormone to be freeze-dried, and placing and fixing the double-cavity clamping bottle on a customized freeze-drying bracket; the top plug is placed in the plug pressing assembly so as to be fixed to the bottle opening of the double-cavity clamping type bottle; performing freezing, primary drying and secondary drying on the to-be-freeze-dried long culture growth hormone respectively; the top plug is fixed by the top cover and the bottle opening is sealed; the plug pressing assembly comprises a pressing-in jig and a maintaining jig, the maintaining jig is attached to the outer wall of the bottle opening, and the top plug is placed in the maintaining jig so that the top plug can be fixed to the bottle opening; the press-in jig presses the top plug to be embedded into the bottle opening, and the plug pressing assembly is removed to complete plug pressing. According to the method disclosed by the invention, high-quality freeze-drying parameters and freeze-drying operation can be provided, and the top plug and the top cover are utilized to complete plug pressing and cover sealing of the double-cavity clamping type bottle, so that the obtained growth hormone freeze-drying preparation for the growth culture keeps better appearance and lower moisture.

The present invention proposes a growth hormone fusion protein and its application. The fusion protein includes an Fc mutant, which includes: a first peptide chain, wherein the first peptide chain 1) has a mutation at the following sites compared to the wild-type IgG4Fc fragment: at least one of the 234th, 235th, 298th, 299th, and 300th positions; or 231-239th positions; or 2) has a mutation at the following sites compared to the wild-type IgG1Fc fragment: at least one of the 228th-239th positions, and / or at least one of the 268th, 296th, 330th, and 331st positions. The fusion protein has a strong binding activity with human growth hormone receptors, can eliminate ADCC and CDC effects, promote Nb2-11 cell proliferation, and thus effectively treat or prevent diseases related to abnormal human growth hormone.

The invention discloses application of a growth hormone receptor antagonist and a nucleic acid molecule in preparation of a medicine for preventing or treating retinal neovascularization diseases, and relates to the technical field of retinal neovascularization. The invention finds that the growth hormone receptor antagonist or the blocking reagent can effectively intervene the occurrence and development of the neovascular retina disease and improve the symptom of the disease. In addition, the transcription level of the encoding gene of the growth hormone receptor is reduced in a gene editing mode, and the pathological vascular change of the retinal neovascular disease can be effectively improved by knocking out the retina GHR, so that the pathological neovascular growth of the retina is reduced, and vascular exudation and inflammatory response are reduced. The invention provides a new direction for the treatment of retinal neovascular diseases, and provides a new choice for patients intolerant or unresponsive to anti-VEGF (Vascular Endothelial Growth Factor) treatment.

The present invention provides for the immediate or chronic administration of certain potassium ATP (K ATP ) channel openers, optionally in combination with growth hormone, to subjects to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic, and compositional outcomes in the treatment of diseases or conditions involving K ATP channels. Also provided are pharmaceutical formulations, methods of administration, and methods of dosing K ATP channel openers to achieve these outcomes and to reduce the incidence of adverse effects in treated individuals. Also provided are methods of co-administering K ATP channel openers with other drugs, e.g., in combination with growth hormone, to treat diseases in humans and animals, e.g., Prader-Willi Syndrome (PWS), Smith-Magenis Syndrome (SMS), etc.

The invention discloses a composition for promoting skeletal growth and physical development of children and a preparation method, the composition comprises a plurality of nutrient elements and Chinese herbal medicine components, and the components have the effects of promoting skeletal health, enhancing immunity, improving nutrient absorption, regulating metabolism, improving sleep quality, promoting secretion of growth hormone and the like. The healthy growth of bones and the overall development of a body are jointly promoted.

The invention discloses nutrition powder for promoting growth of bones of children and a preparation method of the nutrition powder. The nutrition powder comprises trehalose, strawberry fruit powder, L-calcium lactate, maltodextrin, gamma-aminobutyric acid, L-lysine, taurine, bone collagen, zinc gluconate, fructo-oligosaccharide, Chinese yam powder, poria cocos powder, stevioside, VD3 dry powder and VA acetate powder. The trehalose is used for providing energy needed by growth of children, the gamma-aminobutyric acid and the zinc gluconate have the function of promoting pituitary to secrete growth hormone, the L-calcium lactate and the vitamin D3 are used for providing a calcium source needed by growth and ensuring absorption, and the bone collagen is used for providing a protein source for bone production. Chinese yam, poria cocos and fructo-oligosaccharide which are homologous in medicine and food improve the gastrointestinal absorption function of children, the whole formula is comprehensive in consideration and reasonable in nutrition matching, the purpose of promoting bone growth of children is effectively achieved, and the food has the advantages of being low in production cost, easy and convenient to operate, safe to eat and scientific and reasonable in process.

Provided herein are maturation media and methods for maturing early embryonic human cardiac organoids to mature human cardiac organoids. The maturation medium comprises a cell growth medium comprising a medium supplement comprising: one or more fatty acids, a triiodothyronine (T3) growth hormone, insulin, one or more antioxidants, a sugar, and carnitine; one or more additional fatty acids; additional carnitine or creatine; and a further T3 growth hormone. The maturation medium may also include one or more additional sugars, additional antioxidants, and growth factors. The methods include contacting an early embryonic human cardiac organoid with one or more maturation media to produce a mature human cardiac organoid.

The invention discloses a human growth hormone detection antibody and a preparation method thereof. The amino acid sequence of the detection antibody is one of SEQ ID NO. 1 and SEQ ID NO. 2; the preparation method comprises the following steps: extracting RNA (Ribonucleic Acid), performing reverse transcription, amplifying obtained cDN A, inserting into escherichia coli, and constructing a human growth hormone primary library; the M13KO7 auxiliary bacteriophage invades the human growth hormone primary library to construct a bacteriophage primary library; carrying out three rounds of solid phase panning on the phage primary library, and carrying out monoclonal screening, ELISA detection and sequencing to obtain a target gene sequence; and synthesizing the target gene sequence into a prokaryotic expression plasmid, introducing the prokaryotic expression plasmid into escherichia coli, and adding IPTG for expression to obtain the detection antibody. The detection antibody has the characteristics of low economy, strong stability and simple subsequent operation, and solves the problem that animal immunization is always needed to prepare the antibody in the subsequent process in human growth hormone detection.

The invention discloses a growth hormone inhibitor and application of related active substances of the growth hormone inhibitor in preparation of drugs, pharmaceutical compositions, preparations or devices for improving, correcting, slowing down, controlling, treating or preventing ophthalmic diseases or symptoms, and by applying an effective amount of the growth hormone inhibitor to a patient, the ophthalmology, especially myopia-related symptoms of the patient can be obviously improved. And the traditional Chinese medicine composition is good in safety and has a clinical application prospect. The invention also provides a pharmaceutical composition, a preparation and a device containing the growth hormone inhibitor.

This invention relates to treating Prader-Willi Syndrome (PWS) using a KATP channel opener. The channel opener may be coadministered with other therapies used to treat PWS, such as human growth hormone, a wakefulness promoting agent, or a psychiatric or mood stabilizing drug, thereby allowing the baseline dosages of these other therapies to be decreased or making these other therapies unnecessary. The invention also relates to treating PWS based on the PWS nutritional phase of a patient, to prevent the patient's PWS nutritional phase from progressing or shift the patient's PWS nutritional phase back to an earlier phase. The invention further relates to treating PWS, and conditions associated with low basal metabolic rate or hyperphagia, with the KATP channel opener based on a patient's blood ketone levels.

The invention provides a preparation method of yak bone collagen peptide, a composition for promoting skeletal development and application of the composition, and relates to the technical field of health food. The preparation method comprises the following steps: carrying out ultrasonic pretreatment on yak bones, and degreasing through supercritical CO2 to obtain a degreased product; mixing the degreased product with a fishy smell removing agent to obtain a fishy smell removing product; the fishy smell removing agent is an aqueous solution of a plant extract; the plant extract is selected from at least one of amomum tsao-ko extract, turmeric extract, green tea extract or momordica grosvenori extract; the fishy smell removal product is subjected to an enzymatic hydrolysis reaction through an immobilized compound enzyme reactor, wherein the compound enzyme is prolyl endopeptidase, papain and ficin; obtaining a crude product; carrying out ultrafiltration by adopting a filter membrane with the molecular weight cut-off of 1kDa, and adsorbing through macroporous resin. The yak bone collagen peptide and the composition prepared by the invention can obviously improve the body length, promote the skeletal development and promote the secretion of growth hormone, and meet the growth requirements of children.

Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.

The invention provides a regeneration seedling raising method and system for crop seedlings, and the method comprises the steps: extracting a balance value of growth hormone of an explant in a regeneration culture process from the combination information of a hormone receptor in the regeneration culture process of the explant, and determining a light compensation point of a target crop; performing stepped compensation on the illumination period of the target crop through the light compensation points to obtain compensation characteristics of the illumination period in the regeneration culture process; determining the adjustment interval of the seedling raising temperature of the target crop in each culture stage, and performing light-temperature coupling on the illumination intensity of the target crop according to the adjustment interval of each seedling raising temperature and the compensation characteristic of the illumination period to obtain the coupling characteristic of radiation illumination of the explant of the target crop in each culture stage; and performing staged adjustment on radiation illumination in the regeneration culture process based on each coupling characteristic. Based on the scheme, staged coupling adjustment of radiation illumination in the crop seedling culture process can be achieved.

The invention relates to the field of biological immunity and pharmaceutical preparations, and particularly discloses a human growth hormone (GH) freeze-drying protective agent. The invention further discloses a freeze-drying preparation prepared from the freeze-drying protective agent. The freeze-drying preparation mainly comprises the following components in parts by weight: 10-100 mM of a buffer solution, 1-30 parts of a protective agent, a stabilizer and an excipient, 0.01-1.5 parts of a surfactant, 0.1-0.8 part of an antioxidant and 0.05-3 parts of a preservative. The invention provides a specific preparation method of the freeze-dried preparation, the preparation has the advantages of long preservation period, short redissolution time compared with a common reagent, good form and good structural stability after freeze-drying, provides favorable protection conditions for preparation of ELISA standard substances and internal control substances, is beneficial to maintenance of the stability of proteins, and has good application prospects. The specificity and the sensitivity of the ELISA kit are improved.

The invention relates to a low-temperature-resistant azotobacter pseudomonad ZJY-Z1 and application thereof, and belongs to the technical field of microbial agents. The low-temperature-resistant azotobacter pseudomonad ZJY-Z1 disclosed by the invention is preserved in the China General Microbiological Culture Collection Center on February 26, 2025, and the preservation number is CGMCC NO.33670; the low temperature resistant azotobacter pseudomonad ZJY-Z1 has the Latin name of Pseudomonas sp. ZJY-Z1, and the Latin name of the low temperature resistant azotobacter pseudomonad ZJY-Z1 is Pseudomonas sp. ZJY-Z1. The nitrogen-fixing bacterium provided by the invention is resistant to low temperature, has nitrogen fixation capability, can effectively decompose insoluble phosphate, also has certain siderophore production capability and plant growth hormone IAA production capability, and creates more favorable conditions for growth and development of plants.

The invention discloses a marine sediment bacillus CK22 and application thereof, and belongs to the field of microorganisms, the strain is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: M20251027. The strain disclosed by the invention has the capabilities of dissolving potassium, dissolving calcium and magnesium and secreting plant growth hormone and cytokinin, particularly has very excellent capability of dissolving magnesium element, is improved by more than 20 times compared with a control group, has excellent comprehensive capability, and can be used for preparing a microbial fertilizer for promoting the growth of crops.

The invention relates to the technical field of medicine, in particular to an early evaluation method for endocrine remission of pituitary growth hormone adenoma based on low Knosp grading, which comprises the following steps: acquiring preoperative and postoperative image data and preoperative and postoperative clinical data of a patient with low Knosp grading pituitary growth hormone adenoma; extracting imaging features used for early evaluation of postoperative endocrine remission from the preoperative and postoperative image data; extracting clinical features for early evaluation of postoperative endocrine remission from the preoperative and postoperative clinical data; and performing statistical analysis on the iconography characteristics and the clinical characteristics to obtain an early evaluation result of postoperative endocrine remission. According to the method, risk factors related to whether low-Knosp graded pituitary growth hormone adenoma postoperative endocrine remission can be relieved or not are screened out, then a prediction model is established through a statistical method, and then early prediction of low-Knosp graded pituitary growth hormone adenoma postoperative endocrine remission is achieved.

The invention relates to fermented lactobacillus mucus UP-1 and application thereof to improvement of bone metabolism and promotion of growth, and belongs to the technical field of microorganisms, the classification name of the fermented lactobacillus mucus UP-1 is Limosilicobacterium fermentum UP-1, the preservation unit of the fermented lactobacillus mucus UP-1 is China General Microbiological Culture Collection Center, and the preservation number of the fermented lactobacillus mucus UP-1 is CGMCC No.33076; the preservation time is December 16, 2024. The fermented lactobacillus mucus UP-1 provided by the invention can promote the increase of the body length and the thighbone length diameter by increasing the levels of insulin-like growth factor binding protein-3 (IGFBP3), growth hormone (GH) and insulin-like growth factor (IGF-1) in serum, improve the density of bone trabecula and the level of beneficial metabolite short-chain fatty acid, improve the bone metabolism level, promote the growth of a human body and promote the growth of a human body. The health development of bones is promoted, so that the purposes of promoting growth and development and improving nutrient absorption are achieved, and more scientific diet intervention and precise probiotic development are facilitated.

The invention provides a growth hormone fusion protein and application thereof. The fusion protein comprises an Fc mutant, the Fc mutant comprises an amino acid sequence as shown in SEQ ID NO: 49, or the Fc mutant comprises a first peptide chain and a second peptide chain, and the C end of the second peptide chain is connected with the N end of the first peptide chain; wherein a, compared with a wild type IgG4Fc fragment, the first peptide chain has the following mutations: F234V and L235E; or S298N, T299A, and Y300S, or a combination thereof; compared with a hinge region of wild type IgG4, the second peptide chain has S28P mutation; or b, compared with a wild type IgG4Fc fragment, the first peptide chain 1) has 231st-239th amino acid deletion; or (2) compared with a wild type IgG1Fc fragment, the IgG1Fc fragment has the following mutations: the 228th to 239th amino acid deletion, H268Q, Y296F, A330S and P331S. The fusion protein has high binding activity with a human growth hormone receptor, ADCC and CDC effects can be eliminated, Nb2-11 cell proliferation is promoted, and therefore human growth hormone abnormality related diseases are effectively treated or prevented.

The invention discloses a siraitia grosvenorii tissue culture seedling ex-vitro rooting method, belongs to the technical field of plant tissue culture, and mainly solves the problems of long rooting time, untidy root development and low transplanting survival rate in the traditional tissue culture seedling ex-vitro rooting technology. The method comprises the following steps: selecting young branches to prepare sterile explants, and performing hormone-induced culture to obtain robust tissue culture seedlings; a growth hormone combination with a specific ratio is adopted in the rooting pre-culture stage; humidity change is controlled through three-stage gradient seedling hardening; the tissue culture seedlings are transplanted to a matrix after being soaked in a 200-350 mg / L ABT rooting solution. The method remarkably shortens the rooting time, improves the root strength, improves the transplanting survival rate, and can be efficiently used for large-scale production of the virus-free seedlings of momordica grosvenori and resist environmental stress such as late spring coldness.

The application discloses application of SbWOX gene and SbBBM gene in corn breeding and a corn genetic transformation method, and relates to a bioengineering technology.The application provides a nucleic acid molecule with co-expression of SbWOX protein gene and SbBBM protein gene, and corresponding gene co-expression vectors and microbial transformants.The application also provides application of the co-expression of the SbWOX gene and the SbBBM gene in the corn genetic transformation method.The application obtains corresponding genes and mutant proteins based on the SbWOX gene and the SbBBM gene of sorghum, the two genes are co-expressed in the corn genetic transformation process, even without adding plant growth hormones in the antibiotic screening medium in the tissue culture process, the plant genetic transformation process can be normally completed, and the transformation efficiency and the regeneration efficiency of the corn can be remarkably improved, the transformation rate reaches 10.42%, and the differentiation rate reaches 32.89%.

The present invention belongs to the field of bioengineering technology, and specifically relates to a human growth hormone fusion protein and its application. The fusion protein hGH-linker-HSA and the hGH mutant fusion protein hGHmutF31Q / V90E-linker-HSA are constructed by connecting hGH and HSA through a connecting peptide. Mouse experiments show that hGHmutF31Q / V90E-linker-HSA can improve the metabolic stability of hGH, prolong the half-life of hGH, and enhance the administration effect of hGH, and has a broad application prospect in clinical practice.

Described herein are growth hormone receptor antagonists and modified growth hormone receptor antagonists. The growth hormone receptor antagonists and modified growth hormone receptor antagonists are useful in treating diseases or conditions, such as cancer and acromegaly, that are responsive to human growth hormone receptor antagonists.

Described herein is a new method for treating diseases such as non-alcoholic fatty liver disease and non-alcoholic steatohepatitis with a growth hormone secretagogue alone or in combination with a drug selected from a dipeptidyl peptidase-4 antagonist, a glucagon-like peptide receptor agonist, a thiazolidinedione, a sodium glucose transport protein 2 antagonist, and metformin. Compositions relating to the same are also provided.

The present disclosure is directed to transgenic animals (e.g., transgenic porcine animals) comprising multiple genetic modifications that advantageously render these animals suitable donors for xenotransplantation. The present disclosure extends to organs, organ fragments, tissues and cells derived from these animals and their therapeutic use. The present disclosure further extends to methods of making such animals. In certain embodiments, the transgenic animals (e.g., transgenic porcine animals) have reduced expression of the growth hormone receptor (GHR) gene or have impaired function of the GHR protein.

A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and / or prevention of diseases or disorders in which use of growth hormone is beneficial.